Martine Rothblatt Sells 9,500 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the business’s stock in a transaction on Wednesday, June 10th. The stock was sold at an average price of $545.83, for a total transaction of $5,185,385.00. Following the completion of the sale, the chief executive officer directly owned 40,513 shares of the company’s stock, valued at $22,113,210.79. This represents a 19.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

United Therapeutics Stock Up 0.1%

United Therapeutics stock opened at $545.96 on Friday. The company has a market capitalization of $23.18 billion, a PE ratio of 20.15, a P/E/G ratio of 1.78 and a beta of 0.57. The firm has a fifty day simple moving average of $566.75 and a two-hundred day simple moving average of $521.34. United Therapeutics Corporation has a twelve month low of $272.12 and a twelve month high of $609.35.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing the consensus estimate of $7.00 by ($1.18). The firm had revenue of $781.50 million for the quarter, compared to the consensus estimate of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The business’s revenue was down 1.6% on a year-over-year basis. During the same period last year, the company posted $6.63 earnings per share. As a group, equities analysts expect that United Therapeutics Corporation will post 26.84 earnings per share for the current fiscal year.

Analyst Ratings Changes

UTHR has been the topic of a number of recent research reports. UBS Group upped their price objective on shares of United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a report on Thursday, March 5th. Oppenheimer increased their price target on shares of United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a report on Thursday, February 26th. Jefferies Financial Group restated a “buy” rating on shares of United Therapeutics in a research report on Monday, March 2nd. Bank of America increased their price objective on shares of United Therapeutics from $569.00 to $626.00 and gave the company a “neutral” rating in a research report on Tuesday, March 31st. Finally, Royal Bank Of Canada lowered their price objective on shares of United Therapeutics from $707.00 to $701.00 and set an “outperform” rating on the stock in a research report on Thursday, May 7th. Eleven analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, United Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $619.42.

Institutional Investors Weigh In On United Therapeutics

A number of hedge funds have recently modified their holdings of UTHR. Torren Management LLC purchased a new stake in shares of United Therapeutics in the 4th quarter worth $26,000. Activest Wealth Management increased its stake in shares of United Therapeutics by 1,400.0% in the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 56 shares in the last quarter. Entrust Financial LLC purchased a new stake in shares of United Therapeutics in the 4th quarter worth $31,000. International Assets Investment Management LLC increased its stake in shares of United Therapeutics by 426.7% in the 1st quarter. International Assets Investment Management LLC now owns 79 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 64 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB increased its stake in shares of United Therapeutics by 125.6% in the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock worth $37,000 after purchasing an additional 49 shares in the last quarter. Institutional investors own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.